Recent Updates
Recently added Catalysts
PGEN Positive Sentiment Score: 75/100

Precigen to Participate in Upcoming Virtual Fireside Chats Hosted by Cantor and H.C. Wainwright

Monday, August 25, 2025 1 min read
Key Takeaway: Precigen, Inc. announced its participation in two virtual fireside chats hosted by Cantor and H.C. Wainwright. The discussions will focus on the recent FDA approval of a therapy for recurrent respiratory papillomatosis. Key executives from Precigen will represent the company during these events, which are accessible via their website.

Market Sentiment Analysis

POSITIVE FACTORS

  • Precigen is participating in significant virtual fireside chats.
  • The discussions will cover the recent FDA approval of a therapy.
  • The company is focused on innovative precision medicines.

Full Press Release Details

GERMANTOWN, Md.,Aug. 25, 2025/PRNewswire/ --Precigen, Inc.(Nasdaq:PGEN), a biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced that Precigen will participate in two upcoming virtual fireside chats hosted byJennifer Kimof Cantor, and Swayampakula Ramakanth, PhD, of H.C. Wainwright to discuss the recent approval of the first and only FDA-approved therapy for the treatment of adults with recurrent respiratory papillomatosis.

Cantor Virtual Fireside ChatAugust 27, 2025,11 AM–12 PM ETHost:Jennifer Kim, Biotech Analyst, CantorParticipants:Helen Sabzevari, PhD, President and CEO, Precigen andPhil Tennant, Chief Commercial Officer, Precigen

H.C. Wainwright Virtual Fireside ChatSeptember 2, 2025,11 AM–12 PM ETModerator: Swayampakula Ramakanth, PhD, Managing Director, Equity Research,H.C. WainwrightParticipants:Helen Sabzevari, PhD, President and CEO, Precigen andPhil Tennant, Chief Commercial Officer, Precigen

Participants may access the live webcasts of the virtual events through Precigen's website in the Events & Presentations section atinvestors.precigen.com/events-presentations.

Precigen: Advancing Medicine with Precision®Precigen (Nasdaq:PGEN) is a biopharmaceutical company specializing in the advancement of innovative precision medicines to address difficult-to-treat diseases with high unmet patient need. Precigen is dedicated to advancing scientific breakthroughs from proof-of-concept through commercialization. With a strong commitment to innovation, Precigen is developing a robust pipeline of differentiated therapies across its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. For more information about Precigen, visitwww.precigen.comor follow us onLinkedInorYouTube.

Investor Contact:Steven M. HarasymTel: +1 (202) 365-2563[email protected]

Media Contact:Donelle M. Gregory[email protected]

SOURCE Precigen, Inc.

Frequently Asked Questions

What is the purpose of the fireside chats?

The chats will discuss the recent FDA approval of a therapy for recurrent respiratory papillomatosis.

Who will represent Precigen in the chats?

Helen Sabzevari, PhD, and Phil Tennant will represent Precigen.

When are the virtual fireside chats scheduled?

The chats are scheduled for August 27 and September 2, 2025.

How can participants access the events?

Participants can access the live webcasts through Precigen's website.

Tags: PGEN Viatris Investor Conferences Healthcare Precigen FDA approval virtual fireside chat biopharmaceuticals
Last updated: Aug 25, 2025